TRCT
NVCR icon

Tower Research Capital (TRC)’s NovoCure NVCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
9,541
+3,074
+48% +$38.4K ﹤0.01% 2139
2025
Q4 		$83.6K Buy
6,467
+2,056
+47% +$26.4K ﹤0.01% 2064
2025
Q3 		$57K Sell
4,411
-10,410
-70% -$139K ﹤0.01% 2426
2025
Q2 		$264K Buy
14,821
+12,515
+543% +$218K 0.01% 1535
2025
Q1 		$41.1K Buy
2,306
+272
+13% +$6.18K ﹤0.01% 2364
2024
Q4 		$60.6K Sell
2,034
-6,669
-77% -$141K ﹤0.01% 2436
2024
Q3 		$136K Sell
8,703
-16,273
-65% -$295K ﹤0.01% 1980
2024
Q2 		$428K Buy
24,976
+23,233
+1,333% +$409K 0.01% 1465
2024
Q1 		$27.2K Sell
1,743
-7,340
-81% -$108K ﹤0.01% 2731
2023
Q4 		$136K Buy
9,083
+5,260
+138% +$70.4K ﹤0.01% 2402
2023
Q3 		$61.7K Sell
3,823
-4,892
-56% -$141K ﹤0.01% 2367
2023
Q2 		$362K Buy
8,715
+3,122
+56% +$194K 0.01% 1186
2023
Q1 		$337K Sell
5,593
-351
-6% -$28K 0.01% 1073
2022
Q4 		$436K Buy
5,944
+5,206
+705% +$392K 0.02% 778
2022
Q3 		$57K Sell
738
-2,089
-74% -$163K ﹤0.01% 3044
2022
Q2 		$196K Sell
2,827
-7,328
-72% -$552K ﹤0.01% 1780
2022
Q1 		$841K Sell
10,155
-702
-6% -$51.7K 0.01% 864
2021
Q4 		$815K Buy
10,857
+10,553
+3,471% +$1.06M 0.01% 809
2021
Q3 		$35K Sell
304
-11,550
-97% -$1.75M ﹤0.01% 3241
2021
Q2 		$2.63M Buy
11,854
+5,494
+86% +$1.07M 0.07% 229
2021
Q1 		$841K Sell
6,360
-1,820
-22% -$288K 0.01% 868
2020
Q4 		$1.42M Sell
8,180
-1,469
-15% -$201K 0.04% 347
2020
Q3 		$1.07M Sell
9,649
-14,037
-59% -$1.12M 0.01% 916
2020
Q2 		$1.41M Buy
+23,686
New +$1.56M 0.06% 348
2020
Q1 		– Sell
-4,575
Closed -$386K – 3628
2019
Q4 		$386K Buy
+4,575
New +$369K 0.03% 360
2019
Q3 		– Sell
-1,320
Closed -$83K – 4384
2019
Q2 		$83K Buy
1,320
+1,120
+560% +$56.8K 0.01% 1267
2019
Q1 		$10K Buy
200
+100
+100% +$4.81K ﹤0.01% 2686
2018
Q4 		$3K Sell
100
-663
-87% -$24.2K ﹤0.01% 3201
2018
Q3 		$40K Buy
+763
New +$30.4K ﹤0.01% 1902
2018
Q1 		– Sell
-2,845
Closed -$57K – 3670
2017
Q4 		$57K Sell
2,845
-7,155
-72% -$138K 0.01% 1235
2017
Q3 		$199K Buy
10,000
+6,300
+170% +$124K 0.02% 773
2017
Q2 		$64K Buy
+3,700
New +$47.8K 0.01% 651
2016
Q3 		– Sell
-200
Closed -$2K – 4188
2016
Q2 		$2K Sell
200
-814
-80% -$10.2K ﹤0.01% 3933
2016
Q1 		$15K Buy
1,014
+766
+309% +$11K ﹤0.01% 1569
2015
Q4 		$6K Buy
+248
New +$5.92K ﹤0.01% 2792

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Tower Research Capital (TRC)'s NVCR Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its NovoCure (NVCR) stake by 48% in Q1 2026, buying an estimated $38.4K and bringing the position to 9,541 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Tower Research Capital (TRC) first reported a position in NVCR in Q4 2015 and has held it in 35 quarters since. The position peaked at $2.63M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Tower Research Capital (TRC) held 9,541 shares of NovoCure worth $104K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,074 NovoCure shares in Q1 2026, an estimated $38.4K.
  • NovoCure made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2139 holding.
  • Tower Research Capital (TRC) first reported a position in NovoCure in Q4 2015 and has held it in 35 quarters since.
  • Tower Research Capital (TRC)'s NovoCure position peaked at $2.63M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.